At-Risk Women Want Breast Cancer Gene Test--If 'Pros' Outweigh 'Cons'

September 23, 1997

Women who have a family history of breast cancer want to be tested to learn if they have inherited a genetic mutation that predisposes them to the disease -- but only if they believe the benefits of such knowledge outweigh the disadvantages.

A research team at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and Memorial Sloan-Kettering Cancer Center in New York asked 74 women who had close relatives with breast cancer if they were prepared to undergo genetic testing for BCRA1 and BCRA2, the genetic mutations associated with breast cancer. The women were also asked about their perceptions of the pros and cons of such testing.

The researchers report in the September-October issue of Psychosomatic Medicine that 81 percent of the women planned to seek genetic testing, and 46 percent said they were interested in getting tested as soon as possible. For most of them, the readiness to be tested was strongly related to their perceptions that the advantages outweighed the disadvantages.

"Genetic testing provides powerful information and, as this study shows, a woman's desire to be tested hinges largely on her perception that there is more to be gained than lost by having this knowledge," said Paul Jacobsen, PhD, lead author of the study. "These findings underscore the importance of providing counseling to women who plan to undergo genetic testing for breast cancer susceptibility."

Jacobsen, a psychologist at the Moffitt Cancer Center and the University of South Florida, said counseling is needed to help women know how to use their newfound knowledge to their advantage, as well as to prevent adverse psychological reactions and to assist them in evaluating treatment options.

In the study, a majority of women reported that learning about their genetic risk would motivate them to practice breast self-examination more frequently, and help them decide whether to go for more frequent mammograms or undergo preventive surgery.

As scientists identify an increasing number of mutant genes associated with diseases, public debate has focused on fears that employers and insurers might use the results of such tests to discriminate against those who carry the mutant genes. Despite this, most women in the study perceived relatively few disadvantages from genetic testing.

As might be expected, their concerns were related primarily to the possibility of learning they had inherited a susceptibility to breast cancer. In that event, most said they would worry more than they do now about developing breast cancer themselves and about other family members who may also have the gene. About 5 to 10 percent of all breast cancers are attributed to an inherited genetic risk, and women who inherit these genetic mutations have up to a 90 percent chance of developing breast cancer during their lifetime.
-end-

The study was funded by the T.J. Martell Foundation, the American Cancer Society and the U.S. Department of the Army.

To contact Dr. Jacobsen, call (813) 979-3862.

Psychosomatic Medicine is the official peer-reviewed journal of the American Psychosomatic Society, published bi-monthly. For information about the journal, contact Joel E. Dimsdale, MD, editor-in-chief: (619) 543-5468.

Posted by: Center for the Advancement of Health (www.cfah.org)
Contact: Richard Hébert, (202) 387-2829; rhebert@cfah.org
Please also link ink to American Psychosomatic Society: http://www.electriciti.com/~medicine/

Center for Advancing Health

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.